Charles River Laboratories International, Inc.
CRL
$163.71
-$0.40-0.24%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.03B | 984.17M | 1.00B | 1.01B | 1.03B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.03B | 984.17M | 1.00B | 1.01B | 1.03B |
| Cost of Revenue | 648.60M | 644.07M | 688.77M | 642.00M | 658.39M |
| Gross Profit | 383.54M | 340.10M | 313.78M | 367.77M | 367.73M |
| SG&A Expenses | 185.82M | 176.32M | 194.43M | 187.01M | 165.86M |
| Depreciation & Amortization | 25.68M | 29.76M | 41.22M | 32.40M | 28.77M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 860.10M | 850.15M | 924.43M | 861.41M | 853.01M |
| Operating Income | 172.03M | 134.01M | 78.12M | 148.35M | 173.11M |
| Income Before Tax | 71.42M | 35.98M | -216.79M | 91.24M | 119.65M |
| Income Tax Expenses | 18.73M | 10.10M | -3.04M | 20.95M | 25.39M |
| Earnings from Continuing Operations | 52.69M | 25.88M | -213.75M | 70.30M | 94.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -367.00K | -409.00K | -748.00K | -638.00K | -180.00K |
| Net Income | 52.33M | 25.47M | -214.50M | 69.66M | 94.08M |
| EBIT | 172.03M | 134.01M | 78.12M | 148.35M | 173.11M |
| EBITDA | 327.04M | 218.88M | 170.83M | 236.55M | 259.19M |
| EPS Basic | 1.06 | 0.50 | -4.22 | 1.34 | 1.75 |
| Normalized Basic EPS | 1.82 | 1.17 | 0.41 | 1.47 | 1.71 |
| EPS Diluted | 1.06 | 0.50 | -4.22 | 1.33 | 1.74 |
| Normalized Diluted EPS | 1.81 | 1.16 | 0.41 | 1.47 | 1.70 |
| Average Basic Shares Outstanding | 49.15M | 50.68M | 51.14M | 51.39M | 51.55M |
| Average Diluted Shares Outstanding | 49.32M | 50.85M | 51.14M | 51.58M | 51.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |